LP
REGN icon

LMR Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

LMR Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.1M Buy
39,000
+34,000
+680% +$26M 0.07% 158
2025
Q4 		$3.86M Hold
5,000
– – 0.01% 638
2025
Q3 		$2.81M Sell
5,000
-92,800
-95% -$52.5M 0.01% 648
2025
Q2 		$51.3M Buy
+97,800
New +$54.6M 0.37% 53
2024
Q2 		– Sell
-5,200
Closed -$5M – 1274
2024
Q1 		$5M Hold
5,200
– – 0.05% 329
2023
Q4 		$4.57M Hold
5,200
– – 0.05% 328
2023
Q3 		$4.28M Buy
+5,200
New +$4.09M 0.05% 275

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

LMR Partners's REGN Position: Q1 2026 in Review

LMR Partners increased its Regeneron Pharmaceuticals (REGN) stake by 22% in Q1 2026, buying an estimated $19.9K and bringing the position to 143 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #1254.

LMR Partners first reported a position in REGN in Q3 2014 and has held it in 32 quarters since. The position peaked at $22.9M in Q2 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • LMR Partners held 143 shares of Regeneron Pharmaceuticals worth $110K as of Q1 2026.
  • LMR Partners bought 26 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $19.9K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1254 holding.
  • LMR Partners first reported a position in Regeneron Pharmaceuticals in Q3 2014 and has held it in 32 quarters since.
  • LMR Partners's Regeneron Pharmaceuticals position peaked at $22.9M in Q2 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.